Earlier JAK Inhibitor Intervention May Improve Alopecia Areata Outcomes

Lisa Swanson, MD, a pediatric dermatologist at Ada West Dermatology in Boise, Idaho, and an affiliate of St. Louis Children's Hospital, said clinicians should consider introducing oral JAK inhibitors earlier in the treatment course for alopecia areata rather than reserving them as a last-line option. Speaking with Dermatology Times at the Elevate Derm conference in San Diego, Swanson also outlined practical considerations for selecting appropriate candidates for therapy.¹

Oral JAK inhibitors have expanded treatment options for inflammatory skin diseases such as alopecia areata and atopic dermatitis, but patient selection and safety discussions remain important components of prescribing. Swanson emphasized that clinicians should not let concerns about these therapies prevent appropriate patients from receiving treatment.¹

Earlier Intervention for Alopecia Areata

Swanson said oral JAK inhibitors are often reserved until alopecia areata becomes severe, despite growing clinical experience suggesting patients may benefit from earlier treatment. Introducing therapy sooner may improve treatment response and, in some cases, allow patients to discontinue therapy while maintaining hair regrowth, she said. Patients with moderate to severe atopic dermatitis or severe alopecia areata may be appropriate candidates for JAK inhibitors, provided they meet the approved age indication for the specific medication.

We need to be talking about them earlier on. We get better efficacy, and I think in some cases we can even turn it off, and a patient could have a chance down the road of coming off their JAK inhibitor and maintaining their hair. — Lisa Swanson, Md

Assessing Candidacy: The 3 C's

Although Swanson said clinicians should not be afraid of prescribing JAK inhibitors, she emphasized the importance of individualized risk assessment before initiating therapy. She uses what she calls the "3 C's"—cigarettes, clots, and conception—to guide conversations with patients and their families.

Cigarettes, if a patient is a smoker or has been a smoker. Clots, if they've ever had a blood clot. And conception, if they're a female of childbearing potential. — Swanson

Swanson also said patients who are pregnant or actively planning pregnancy should generally wait before beginning JAK inhibitor therapy, making family planning an important part of treatment discussions.

Starting With Alopecia Areata Patients

For clinicians hesitant to begin prescribing JAK inhibitors, Swanson suggested starting with patients who have alopecia areata. Beyond the visible clinical improvements, she said these patients often experience meaningful gains in confidence and quality of life, making treatment especially rewarding for both patients and clinicians.

Treating alopecia areata patients with oral JAK inhibitors is going to change the lives of everybody involved. Your patient for sure, their family definitely, but also for the prescriber, it's really wonderful to see these patients march through this journey on their oral JAK inhibitor, regrow their hair, regain their confidence. — Lisa Swanson, MD,

Swanson added that patients with severe alopecia areata are often highly motivated to pursue treatment, which can make initiating therapy less intimidating for clinicians still becoming familiar with JAK inhibitors.

I kind of joke you could read the contents of the entirety of the box warning verbatim in an ominous tone to a patient with severe alopecia areata, and at the end of that, they would say, 'Okay, can we start today?' — Swanson

REFERENCES:

1. Swanson L. Interview with Dermatology Times. Conducted at the Elevate-Derm Summer Conference; July 29, 2026; San Diego, CA.
2. Elevate-Derm Alliance. Elevate-Derm Summer Conference 2026. Accessed July 29, 2026. https://www.elevate-derm.com/summer2026